270 Longwood Road South
Hamilton, ON L8P 0A6
Canada
289 799 0891
https://www.fusionpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 101
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. John F. Valliant Ph.D. | Founder, CEO & Director | 911.34k | N/A | 1971 |
Mr. Mohit Rawat | President & Chief Business Officer | 706.08k | N/A | 1980 |
Mr. John J. Crowley CPA | CFO & Compliance Officer | 719.82k | N/A | 1974 |
Dr. Eric Burak Ph.D. | Chief Technology Officer | 638.04k | N/A | 1965 |
Dr. Christopher Paul Leamon Ph.D. | Chief Scientific Officer | N/A | N/A | 1966 |
Ms. Amanda Cray | Senior Director of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Ms. Maria D. Stahl | Chief Legal Officer | N/A | N/A | 1971 |
Mr. Eric S. Hoffman Ph.D. | Senior Vice President of Business Development | N/A | N/A | 1970 |
Dr. Cara Ferreira Ph.D. | Chief of Staff | N/A | N/A | N/A |
Dr. Joanne Schindler | Executive Vice President of Medical Director & Clinical Development | N/A | N/A | N/A |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.